Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina

  • Zumreta Kušljugić Department of Cardiology, University Clínics Center Tuzla
  • Katarina Divković Department of Cardiology, University Clínics Center Tuzla
  • Fahir Baraković Department of Cardiology, University Clínics Center Tuzla
  • Elnur Smajić Department of Cardiology, University Clínics Center Tuzla
  • Amila Arslanagić Department of Cardiology University of Sarajevo Clinics Centre
  • Mustafa Hadžiomerović Department of Internal Medicine, Clinics Hospital Mostar
  • Emir Fazlibegović Department of Internal Medicine, Clinics Hospital Mostar
  • Zlatico Midžić Department of Internal Medicine, Cantonal Hospital Bihać
  • Enes Abdović Department of Internal Medicíne, Cantonal Hospital Zenica
  • Milenko Krneta Department of Internal Medicíne, Cantonal Hospital Zenica
  • Radenko Čelik Private Practice "INTERMEDIC" Banja Luka
  • Hajro Bašić Internal Medicíne Unit, Health Centre Modrica
  • Bajro Avdić Department of Internal Medicine, General Hospital Sarajevo
  • Adnan Delić Department of Cardiology, University Clínics Center Tuzla
  • Amra Macić-Džanković Department of Internal Medicine, General Hospital Sarajevo
  • Nedžad Kečo Berlin-Chemie Representative Office for Bosnia and Herzegovina
  • Hajra Boškailo General Unit, Health Centre Vogošća
Keywords: arterial hypertension, endothelial dysfunction, nebivolol

Abstract

Hypertension is a major risk factor for cardiovascular diseases; drugs that reduce blood pressure and simultaneously improve or reverse endothelian dysfunction, as nebivolol, may be advantageous in terms of cardiovascular protection. The objective of this study is to show the anti-hypertensive efficacy and safety of nebivolol (5 mg once a day) given to patients with arterial hypertension for 3 months. It should also provide information about drug's influence on laboratory tests--fasting blood glucose and serum cholesterol, triglyceride and creatinine concentrations. Six centers--Tuzla, Sarajevo, Mostar, Bihac, Zenica and Banja Luka participated in this prospective study with follow-up period of 3 months that included 3 visits. The study group consisted of 328 hypertensic patients. Results showed a significant decrease in both systolic and diastolic blood pressure and heart rate at the end of the study. Fasting blood glucose level and serum cholesterol, triglyceride and creatinine changed significantly during the study, with lower levels of all the tests. Nebivolol seems to be free from some of the problems that generally accompany not only the classical beta- blockers but sometimes also newer classes of antihypertensive drugs. With its high anti-hypertensive efficiency and safety, and presence of statically significant difference in laboratory tests and beneficial effects, absence of adverse interaction with glucose and lipid metabolism, patients treated with Nebivolol may show an optimal adherence to therapy.

Downloads

Download data is not yet available.
Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina
Published
2005-02-20
How to Cite
1.
Kušljugić Z, Divković K, Baraković F, Smajić E, Arslanagić A, Hadžiomerović M, Fazlibegović E, Midžić Z, Abdović E, Krneta M, Čelik R, Bašić H, Avdić B, Delić A, Macić-Džanković A, Kečo N, Boškailo H. Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina. Bosn J of Basic Med Sci [Internet]. 2005Feb.20 [cited 2020Oct.1];5(1):42-1. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/3334
Section
Translational and Clinical Research